東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Targeting the DNA damage response fo...

Yap, Timothy A.

FindBook

Google Book

Amazon

博客來

Targeting the DNA damage response for cancer therapy

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Targeting the DNA damage response for cancer therapy/ edited by Timothy A. Yap, Geoffrey I. Shapiro.
其他作者:	Yap, Timothy A.
出版者:	Cham :Springer International Publishing : : 2023.,
面頁冊數:	x, 328 p. :illustrations, digital ;24 cm.
內容註:	Evolution of the development of PARP inhibitors -- Exploiting cancer synthetic lethality in cancer - Lessons learnt from PARP inhibitors -- Mechanisms of PARP inhibitor resistance -- Development of homologous recombination functional assays for targeting the DDR -- Clinical application of Poly(ADP Ribose) Polymerase (PARP) inhibitors in ovarian cancer -- Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer -- Development of PARP inhibitors in targeting castration-resistant prostate cancer -- Strategies for the management of patients with pancreatic cancer with PARP inhibitors -- Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: Promise and challenges -- Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents -- Combining PARP inhibition and immunotherapy in BRCA-associated cancers -- Mitotic MTH1 inhibitors in treatment of cancer -- Targeting ATR in cancer medicine -- Targeting polymerase Theta (POLq) for cancer therapy -- Targeting DNA-PK -- WRN is a promising synthetic lethal target for cancers with microsatellite instability (MSI)
Contained By:	Springer Nature eBook
標題:	Cancer - Treatment. -
電子資源:	https://doi.org/10.1007/978-3-031-30065-3
ISBN:	9783031300653

Targeting the DNA damage response for cancer therapy
Targeting the DNA damage response for cancer therapy[electronic resource] /edited by Timothy A. Yap, Geoffrey I. Shapiro. - Cham :Springer International Publishing :2023. - x, 328 p. :illustrations, digital ;24 cm. - Cancer treatment and research,v. 1862509-8497 ;. - Cancer treatment and research ;v. 186..

Evolution of the development of PARP inhibitors -- Exploiting cancer synthetic lethality in cancer - Lessons learnt from PARP inhibitors -- Mechanisms of PARP inhibitor resistance -- Development of homologous recombination functional assays for targeting the DDR -- Clinical application of Poly(ADP Ribose) Polymerase (PARP) inhibitors in ovarian cancer -- Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer -- Development of PARP inhibitors in targeting castration-resistant prostate cancer -- Strategies for the management of patients with pancreatic cancer with PARP inhibitors -- Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: Promise and challenges -- Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents -- Combining PARP inhibition and immunotherapy in BRCA-associated cancers -- Mitotic MTH1 inhibitors in treatment of cancer -- Targeting ATR in cancer medicine -- Targeting polymerase Theta (POLq) for cancer therapy -- Targeting DNA-PK -- WRN is a promising synthetic lethal target for cancers with microsatellite instability (MSI)

This book discusses the latest developments in Poly (ADP-ribose) polymerase (PARP) inhibitor drug development. It focuses on the translational and clinical development of the latest drugs, as well as the evidence for regulatory approval of PARP inhibitors in multiple different molecular subtypes and tumor indications. The most-up-to-date information on basic scientific research on DNA repair pathways and the DNA Damage Response (DDR) is also covered. Every chapter contains insight into the preclinical, translational along with clinical aspects of a specific DDR inhibitor with key and expert opinion points reinforcing the most important concepts detailed to enable the reader to develop a deep understanding of the topic. Targeting the DNA Damage Response for Cancer Therapy comprehensively reviews the application of PARP and other DDR inhibitors across oncology disciplines. Therefore, it is a valuable resource for all medical professionals and researchers who use or who are researching the use of these inhibitors on a day-to-day basis.

ISBN: 9783031300653

Standard No.: 10.1007/978-3-031-30065-3doiSubjects--Topical Terms:

618125
Cancer
--Treatment.

LC Class. No.: RC270.8

Dewey Class. No.: 616.99406

Targeting the DNA damage response for cancer therapy
LDR:03253nmm a2200337 a 4500 001 2336318
003 DE-He213
005 20231117181003.0
006 m d
007 cr nn 008maaau
008 240402s2023 sz s 0 eng d
020 $a 9783031300653 $q (electronic bk.)
020 $a 9783031300646 $q (paper)
024 7 $a 10.1007/978-3-031-30065-3 $2 doi
035 $a 978-3-031-30065-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC270.8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99406 $2 23
090 $a RC270.8 $b .T185 2023
245 0 0 $a Targeting the DNA damage response for cancer therapy $h [electronic resource] / $c edited by Timothy A. Yap, Geoffrey I. Shapiro.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a x, 328 p. : $b illustrations, digital ; $c 24 cm.
490 1 $a Cancer treatment and research, $x 2509-8497 ; $v v. 186
505 0 $a Evolution of the development of PARP inhibitors -- Exploiting cancer synthetic lethality in cancer - Lessons learnt from PARP inhibitors -- Mechanisms of PARP inhibitor resistance -- Development of homologous recombination functional assays for targeting the DDR -- Clinical application of Poly(ADP Ribose) Polymerase (PARP) inhibitors in ovarian cancer -- Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer -- Development of PARP inhibitors in targeting castration-resistant prostate cancer -- Strategies for the management of patients with pancreatic cancer with PARP inhibitors -- Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: Promise and challenges -- Rational combinations of PARP inhibitors with HRD-inducing molecularly targeted agents -- Combining PARP inhibition and immunotherapy in BRCA-associated cancers -- Mitotic MTH1 inhibitors in treatment of cancer -- Targeting ATR in cancer medicine -- Targeting polymerase Theta (POLq) for cancer therapy -- Targeting DNA-PK -- WRN is a promising synthetic lethal target for cancers with microsatellite instability (MSI)
520 $a This book discusses the latest developments in Poly (ADP-ribose) polymerase (PARP) inhibitor drug development. It focuses on the translational and clinical development of the latest drugs, as well as the evidence for regulatory approval of PARP inhibitors in multiple different molecular subtypes and tumor indications. The most-up-to-date information on basic scientific research on DNA repair pathways and the DNA Damage Response (DDR) is also covered. Every chapter contains insight into the preclinical, translational along with clinical aspects of a specific DDR inhibitor with key and expert opinion points reinforcing the most important concepts detailed to enable the reader to develop a deep understanding of the topic. Targeting the DNA Damage Response for Cancer Therapy comprehensively reviews the application of PARP and other DDR inhibitors across oncology disciplines. Therefore, it is a valuable resource for all medical professionals and researchers who use or who are researching the use of these inhibitors on a day-to-day basis.
650 0 $a Cancer $x Treatment. $3 618125
650 0 $a DNA damage. $3 916185
650 0 $a DNA repair. $3 916186
650 1 4 $a Oncology. $3 751006
650 2 4 $a Radiation Oncology. $3 3593533
650 2 4 $a Pharmacology. $3 634543
700 1 $a Yap, Timothy A. $3 3504388
700 1 $a Shapiro, Geoffrey I. $3 3669331
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Cancer treatment and research ; $v v. 186. $3 3669332
856 4 0 $u https://doi.org/10.1007/978-3-031-30065-3
950 $a Medicine (SpringerNature-11650)